(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of -21.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Ptc Therapeutics's revenue in 2025 is $1,772,758,000.On average, 6 Wall Street analysts forecast PTCT's revenue for 2025 to be $138,417,628,262, with the lowest PTCT revenue forecast at $134,193,308,407, and the highest PTCT revenue forecast at $141,457,927,511. On average, 6 Wall Street analysts forecast PTCT's revenue for 2026 to be $72,874,530,517, with the lowest PTCT revenue forecast at $63,167,844,143, and the highest PTCT revenue forecast at $101,528,241,339.
In 2027, PTCT is forecast to generate $91,719,551,182 in revenue, with the lowest revenue forecast at $78,177,934,686 and the highest revenue forecast at $110,971,001,840.